Best Biotech Stocks To Invest In Right Now

Its time for the final push.

With only a handful of trading weeks remaining in 2017, little stands in the way of higher prices.

This years stock market melt-up has produced a long list of incredible winners. The FAANGs, semiconductors, and other big tech stocks have helped fuel the rally. Weve also had multiple chances to profit from the big biotech comeback and the rebirth of homebuilder stocks two more powerful market stories that have led to impressive gains this year.

Many of these stocks will continue to sneak higher during the holiday season. Once again, this rally rewards patient traders and investors who arent afraid to ride the markets most powerful trends.

But theres one group of stocks flying under the radar as melt-up season accelerates…

Unfortunately, many investors have a bad habit of ignoring some of the markets strongest plays simply because they dont know much about the companies responsible for the gains. Theyre caught up in the big narratives the media pipes into our skulls every day.

Best Biotech Stocks To Invest In Right Now: Proteon Therapeutics, Inc.(PRTO)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Proteon Therapeutics Inc (NASDAQ: PRTO) got a boost, shooting up 31 percent to $1.70 after the company disclosed that it has received the FDA Breakthrough Therapy designation for Vonapanitase. Proteon Therapeutics posted a narrower-than-expected quarterly loss.

Best Biotech Stocks To Invest In Right Now: Opexa Therapeutics, Inc.(OPXA)

Advisors’ Opinion:

  • [By Elizabeth Balboa]

    Opexa Therapeutics Inc (NASDAQ: OPXA) and Acer Therapeutics announced a merger that will result in 11.2-percent ownership by current Opexa shareholders and 88.8-percent ownership by current Acer shareholders.

  • [By Lisa Levin]

    Opexa Therapeutics Inc (NASDAQ: OPXA) shares were also up, gaining 66 percent to $1.08 after the company announced plans to acquire Acer Therapeutics.

  • [By Lisa Levin]

    Opexa Therapeutics Inc (NASDAQ: OPXA) shares dropped 70 percent to $1.02 after the company disclosed that its top-line results from Phase 2b Abili-T trial evaluating Tcelna did not meet primary endpoint.

Best Biotech Stocks To Invest In Right Now: Coca-Cola Bottling Co. Consolidated(COKE)

Advisors’ Opinion:

  • [By Douglas A. McIntyre]

    Coca-Cola Bottling Co. (NYSE: COKE) had a revenue increase to $2.3 billion in its most recentfiscal year, from $1.7 billion in the previous one. It is moving into Ohio, Indiana, Kentucky, Illinois and West Virginia, which almost certainly will require capital. Its net sales rose 37% in the most recent quarter to $840 million. Management stated this was because of “Organic growth in the legacy territories as well as territory expansion through the acquisition of several new distribution territories from Coca-Cola led to the solid performance.” The current dividend is $1, or 0.66%.